A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.

Abstract:

:We studied the efficacy, tolerability and clinical courses of dabrafenib in patients with metastatic melanoma who were ineligible for enrolment into a clinical trial. Between July 2011 and May 2013, patients with unresectable stage III or stage IV, V600-mutated metastatic melanoma who were not eligible for inclusion into clinical trials were offered treatment with dabrafenib through a named patient programme. Routine efficacy and toxicity data were collected throughout treatment and studied retrospectively. The endpoints were progression-free survival (PFS), overall survival and best overall response. Thirty-one patients commenced dabrafenib therapy including six individuals who had progressed on a prior BRAF-inhibitor treatment. The majority of patients had cerebral metastases (n=17) and/or a poor performance status [Eastern Cooperative Oncology Group (ECOG)≥2, n=11]. Median overall survival was 5.6 months (range 0.1-22 months). Median PFS was 3.3 months (range 0.1-21) and was similar despite performance status. One patient had a complete response and eight showed partial responses to treatment. Patients with cerebral metastases (n=17) had a median PFS of 4.6 months. Five patients (16%) had dose-limiting toxicities. Despite several poor prognostic features, dabrafenib is a safe and effective treatment in the community setting, with occasional impressive outcomes.

journal_name

Melanoma Res

journal_title

Melanoma research

authors

Lau DK,Andrews MC,Turner N,Azad AA,Davis ID,Cebon JS

doi

10.1097/CMR.0000000000000036

subject

Has Abstract

pub_date

2014-04-01 00:00:00

pages

144-9

issue

2

eissn

0960-8931

issn

1473-5636

journal_volume

24

pub_type

杂志文章
  • Routine retrieval of pelvic sentinel lymph nodes for melanoma rarely adds prognostic information or alters management.

    abstract::Pelvic sentinel lymph nodes (SLNs) are commonly identified during inguinal SLN biopsy for melanoma, but retrieval is not uniform among surgeons/centers. Few studies have assessed rates of micrometastases in pelvic versus superficial inguinal SLNs. Previous studies suggested that presence of pelvic SLNs was predicted b...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000498

    authors: Swords DS,Andtbacka RHI,Bowles TL,Hyngstrom JR

    更新日期:2019-02-01 00:00:00

  • Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma.

    abstract::Ophthalmological complications constitute a class effect of treatment with BRAF inhibitors. Encorafenib is a new BRAF inhibitor currently being tested in phase 3 clinical trials for advanced or metastatic melanoma as monotherapy or in combination with the MEK-inhibitor binimetinib. In this study, we present a case of ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000505

    authors: Diamantopoulos PT,Stoungioti S,Anastasopoulou A,Papaxoinis G,Gogas H

    更新日期:2018-12-01 00:00:00

  • Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.

    abstract::Ipilimumab, a fully human, recombinant, monoclonal antibody to cytotoxic T-lymphocyte antigen 4 improves overall survival (OS) in previously treated and untreated metastatic melanoma. This retrospective analysis reports data gathered by a questionnaire on the demographics, outcomes, and toxicity of ipilimumab administ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000108

    authors: Berrocal A,Arance A,Lopez Martin JA,Soriano V,Muñoz E,Alonso L,Espinosa E,Lopez Criado P,Valdivia J,Martin Algarra S,Spanish Melanoma Group.

    更新日期:2014-12-01 00:00:00

  • Expression and clinical significance of S100 family genes in patients with melanoma.

    abstract::Genes in the S100 family are abnormally expressed in a variety of tumor cells and are associated with clinical pathology, but their prognostic value in melanoma patients has not yet been fully elucidated. In this study, we extracted and profiled S100 family mRNA expression data and corresponding clinical data from the...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000512

    authors: Xiong TF,Pan FQ,Li D

    更新日期:2019-02-01 00:00:00

  • Inositol hexaphosphate plus inositol induced complete remission in stage IV melanoma: a case report.

    abstract::Inositol hexaphosphate (IP6) also called phytic acid is a polyphosphorylated carbohydrate naturally found in cereals, nuts, grains, and high-fiber-containing foods. It has been shown to inhibit the growth of many different tumor cell lines both in vitro and in vivo like colon, pancreas, liver, prostate, and even melan...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000577

    authors: Khurana S,Baldeo C,Joseph RW

    更新日期:2019-06-01 00:00:00

  • Clinical significance of serum M30 and M65 levels in melanoma.

    abstract::M30 and M65 are relatively new assays that detect different circulating forms of the epithelial cell structural protein cytokeratin 18. This study was carried out to investigate the serum levels of M30 and M65 in patients with melanoma and the relationship with tumor progression and known prognostic parameters. Fifty-...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e328363e4ab

    authors: Tas F,Karabulut S,Serilmez M,Yildiz I,Sen F,Ciftci R,Duranyildiz D

    更新日期:2013-10-01 00:00:00

  • Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases.

    abstract::Microsatellite instability (MSI) is caused by replication errors due to deficient DNA mismatch repair and has been associated with tumour progression in various types of cancer. Controversial results have been reported concerning the frequency and significance of MSI in malignant melanoma. In this study, the time of o...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200304000-00009

    authors: Palmieri G,Ascierto PA,Cossu A,Colombino M,Casula M,Botti G,Lissia A,Tanda F,Castello G

    更新日期:2003-04-01 00:00:00

  • Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

    abstract::BRAF mutations are found in ~50% of metastatic melanomas, most commonly in codon V600. Vemurafenib improves progression-free survival and overall survival in patients with advanced BRAF-mutated melanoma. The results of a descriptive study evaluating vemurafenib in patients with advanced melanoma harbouring BRAF mutati...

    journal_title:Melanoma research

    pub_type: 杂志文章,多中心研究

    doi:10.1097/CMR.0000000000000398

    authors: Hallmeyer S,Gonzalez R,Lawson DH,Cranmer LD,Linette GP,Puzanov I,Taback B,Cowey CL,Ribas A,Daniels GA,Moore T,Gibney GT,Tawbi H,Whitman E,Lee G,Mun Y,Liu S,Hamid O

    更新日期:2017-12-01 00:00:00

  • Serum zinc levels are increased in melanoma patients.

    abstract::We studied the levels of serum copper and zinc as possible diagnostic factors or markers for the early detection of patients with melanoma. Levels were determined in 35 melanoma patients at various clinical stages and in 39 healthy persons. Measurements were performed by atomic absorption spectroscopy using 5100-PC-Pe...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:

    authors: Ros-Bullón MR,Sánchez-Pedreño P,Martínez-Liarte JH

    更新日期:1998-06-01 00:00:00

  • Ribonucleotide diphosphate reductase from human metastatic melanoma.

    abstract::Cell free extracts from metastases of human melanoma contain a highly active ribonucleoside diphosphate reductase (RR) which uses guanosine diphosphate (GDP) as substrate and deoxythymidine triphosphate (dTTP) as effector. No activity could be detected in these extracts when cytidine diphosphate (CDP) was used as the ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199212000-00014

    authors: Schallreuter KU,Elgren TE,Nelson LS Jr,MacFarlan S,Yan-Sze I,Hogenkamp HP

    更新日期:1992-12-01 00:00:00

  • Production of superoxide by human malignant melanoma cells.

    abstract::Metastasis is a complicated multi-step process involving interactions between tumour cells, the extracellular matrix and the vessel walls. Experimental observations suggest that leucocyte migration and function could be a suitable model in order to understand tumour cell dissemination. In the present report we show an...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199810000-00001

    authors: Bittinger F,González-García JL,Klein CL,Brochhausen C,Offner F,Kirkpatrick CJ

    更新日期:1998-10-01 00:00:00

  • Comparing survival outcomes in early stage desmoplastic melanoma with or without adjuvant radiation.

    abstract::Desmoplastic melanoma (DM) due to its rare and locally aggressive nature, can be difficult to study and to treat effectively. Whether the optimal treatment approach for these tumors should include adjuvant radiation has been unclear in the literature. In this retrospective study of the National Cancer Database, 2390 p...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000532

    authors: Abbott JL,Qureshi MM,Truong MT,Sahni D

    更新日期:2019-08-01 00:00:00

  • 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact.

    abstract::Staging of melanoma patients by means of whole body functional imaging in a single evaluation session using positron emission tomography (PET) with fluorine-18- labelled deoxy-d-glucose (FDG) as a metabolic tracer has created much interest over the last decade. After enthusiastic pilot studies, more attention has been...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200209000-00010

    authors: Stas M,Stroobants S,Dupont P,Gysen M,Hoe LV,Garmyn M,Mortelmans L,Wever ID

    更新日期:2002-10-01 00:00:00

  • Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells.

    abstract::The management of metastatic melanoma is a difficult matter. Nevertheless, the advent of target therapy has significantly improved patient outcome, provided that tumor molecular characteristics become available: the detection of drug-resistant clones can contribute to understanding the reasons for resistance onset, in...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000510

    authors: Scaini MC,Pigozzo J,Pizzi M,Manicone M,Chiarion-Sileni V,Zambenedetti P,Rugge M,Zanovello P,Rossi E,Zamarchi R,Facchinetti A

    更新日期:2019-02-01 00:00:00

  • Enhanced effects of multiple treatment electrochemotherapy.

    abstract::Electrochemotherapy has been demonstrated to be an effective treatment for cutaneous cancers. The treatment includes administering a chemotherapeutic agent followed by electric pulses which are applied directly to the tumour. The pulses facilitate delivery of drug through the plasma membrane. Enhanced delivery is rest...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199612000-00004

    authors: Jaroszeski MJ,Gilbert R,Perrott R,Heller R

    更新日期:1996-12-01 00:00:00

  • Comparison of in vivo anti-melanoma effect of enantiomeric alpha-methyl- and alpha-ethyl-4-S-cysteaminylphenol.

    abstract::Melanogenesis appears to be a unique target to develop anti-tumour agents specific for malignant melanoma. Among the anti-melanoma compounds that we have examined, 4-S-cysteaminylphenol (4-S-CAP), a phenolic amine, was found to have the most promising anti-melanoma effects. To further improve the efficacy as anti-mela...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200404000-00006

    authors: Yukitake J,Otake H,Inoue S,Wakamatsu K,Ito S

    更新日期:2004-04-01 00:00:00

  • Protein tyrosine kinases in malignant melanoma.

    abstract::Protein tyrosyl phosphorylation is an essential component in intracellular signalling, with diverse and crucial functions including mediation of cell proliferation, survival, death, differentiation, migration and attachment. It is regulated by the balance between the activities of protein tyrosine kinases (PTKs) and p...

    journal_title:Melanoma research

    pub_type: 杂志文章,评审

    doi:10.1097/00008390-200010000-00001

    authors: Easty DJ,Bennett DC

    更新日期:2000-10-01 00:00:00

  • Synchronous high-risk melanoma and lymphoid neoplasia.

    abstract::Large population-based studies have shown a significant association between melanoma and lymphoid neoplasia, particularly non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukaemia (CLL), that is independent of any treatment received for the initial tumour. This study examines the presentation, diagnosis, treatmen...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200110000-00012

    authors: Cahill RA,McGreal G,Neary P,Redmond HP

    更新日期:2001-10-01 00:00:00

  • Snail-regulated genes in malignant melanoma.

    abstract::The demonstration that zinc-finger transcriptional repressors can control E-cadherin expression in epithelial cells has provided a new avenue of research in the field of epithelial-mesenchymal transition (EMT). One of these zinc-finger molecules is the transcription factor Snail, which controls gastrulation and neural...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200508000-00012

    authors: Kuphal S,Palm HG,Poser I,Bosserhoff AK

    更新日期:2005-08-01 00:00:00

  • Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine.

    abstract::Immunosuppressed patients are at increased risk of skin cancer. A 67-year-old renal transplant recipient developed a nodular malignant melanoma after 30 years of immunosuppression with azathioprine and prednisolone. The patient died of metastatic disease 3 months after the diagnosis was made. The function of the renal...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e32831bc44a

    authors: Guenova E,Lichte V,Hoetzenecker W,Woelbing F,Moehrle M,Roecken M,Schaller M

    更新日期:2009-08-01 00:00:00

  • Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma.

    abstract::The aim was to evaluate toxicity and oncological outcome of combined stereotactic radiosurgery (SRS) and immunotherapy or targeted therapy in patients with multiple brain metastases originating from malignant melanoma. Despite the fact that both SRS and kinase inhibitors or immune checkpoint inhibitors are considered ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000542

    authors: Stera S,Balermpas P,Blanck O,Wolff R,Wurster S,Baumann R,Szücs M,Loutfi-Krauss B,Wilhelm ML,Seifert V,Rades D,Rödel C,Dunst J,Hildebrandt G,Arnold A,Meissner M,Kähler KC

    更新日期:2019-04-01 00:00:00

  • The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis.

    abstract::Recently, TROG 02.01 results showed that in stage III melanoma patients with nodal metastasis, adjuvant radiation to lymph node basin after nodal dissection improves lymph node field relapse without an overall survival (OS) benefit. However, this trial was neither designed nor powered to detect an OS difference. In th...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000292

    authors: Danish HH,Patel KR,Switchenko JM,Gillespie TW,Jhaveri J,Chowdhary M,Abugideiri M,Delman KA,Lawson DH,Khan MK

    更新日期:2016-12-01 00:00:00

  • A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.

    abstract::A vaccine that could expand melanoma-specific T cells might reduce the risk of recurrence of resected melanoma and could provide an alternative or adjunct to standard immunotherapy options. We tested the safety and immunogenicity of a vaccine coupling a melanoma-associated peptide with a xenogenic peptide (to promote ...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章

    doi:10.1097/CMR.0000000000000556

    authors: Block MS,Nevala WK,Pang YP,Allred JB,Strand C,Markovic SN

    更新日期:2019-08-01 00:00:00

  • Ultrasound-guided core needle biopsy of superficial lymph nodes: an alternative to fine-needle aspiration cytology for the diagnosis of lymph node metastasis in cutaneous melanoma.

    abstract::To investigate the diagnostic value of ultrasound-guided core needle biopsy (US-CNB) in suspected cases of lymph node metastasis from cutaneous melanoma. All patients with cutaneous melanoma followed in Saint-Louis Hospital between 2006 and 2010 who underwent US-CNB for suspicion of melanoma lymph node metastasis were...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000161

    authors: Bohelay G,Battistella M,Pagès C,de Margerie-Mellon C,Basset-Seguin N,Viguier M,Kerob D,Madjlessi N,Baccard M,Archimbaud A,Comte C,Mourah S,Porcher R,Bagot M,Janin A,De Kerviler E,Lebbé C

    更新日期:2015-12-01 00:00:00

  • Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature.

    abstract::Checkpoint inhibitor immunotherapy is a transformative treatment for advanced malignancies, but can be associated with numerous immune-related adverse events (irAEs). The majority of irAEs include those that closely resemble known cutaneous and neurocutaneous autoimmune or autoinflammatory diseases, such as scleroderm...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000642

    authors: Kosche C,Stout M,Sosman J,Lukas RV,Choi JN

    更新日期:2020-06-01 00:00:00

  • Sentinel lymph node dissection in stage I/II melanoma patients: surgical management and clinical follow-up study.

    abstract::Selective sentinel lymph node (SLN) dissection is widely used in the management of cutaneous melanoma patients without clinical evidence of nodal metastases. A series of 274 consecutive melanoma patients who underwent melanoma primary excision and SLN mapping at our institutions since 1998, and were thereafter followe...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章

    doi:10.1097/00008390-200404000-00016

    authors: Macripò G,Quaglino P,Caliendo V,Ronco AM,Soltani S,Giacone E,Pau S,Fierro MT,Bernengo MG

    更新日期:2004-04-01 00:00:00

  • Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.

    abstract::Microphthalmia transcription factor (Mitf) is involved in melanocyte development and differentiation. We previously reported that Mitf expression, as detected by immunohistochemical analysis, is an independent prognostic marker in patients with intermediate-thickness melanoma. However, the clinical significance of Mit...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000195

    authors: Naffouje S,Naffouje R,Bhagwandin S,Salti GI

    更新日期:2015-12-01 00:00:00

  • Redox regulation of Brn-2/N-Oct-3 POU domain DNA binding activity and proteolytic formation of N-Oct-5 during melanoma cell nuclear extraction.

    abstract::Reversible oxidation sensitivity of N-Oct-3 DNA binding activity was seen when melanoma extracts and recombinant Brn-2 protein were treated with a variety of metals, hydrogen peroxide and the cysteine disulphide bond forming agent diamide. Western blot analysis of diamide-oxidized N-Oct-3 protein indicated that this w...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199802000-00002

    authors: Smith AG,Brightwell G,Smit SE,Parsons PG,Sturm RA

    更新日期:1998-02-01 00:00:00

  • The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival.

    abstract::The management of melanoma brain metastases (MBM) includes different therapeutic modalities, such as surgery, radiotherapy and chemotherapy. Despite the choice of treatments, survival remains poor, exceeding 1 year only in patients with solitary metastases and absence of extracranial disease. A total of 115 consecutiv...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000029

    authors: Vecchio S,Spagnolo F,Merlo DF,Signori A,Acquati M,Pronzato P,Queirolo P

    更新日期:2014-02-01 00:00:00

  • Sphere formation and self-renewal capacity of melanoma cells is affected by the microenvironment.

    abstract::Melanomas contain subsets of cancer stem-like cells with tumor-initiating capacity. The frequency of these cells in the tumor is still a topic of debate. We investigated the phenotypic plasticity of cancer cells grown as melanospheres to elucidate the influence of the microenvironment on some features of melanoma stem...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e3283531317

    authors: Sztiller-Sikorska M,Koprowska K,Jakubowska J,Zalesna I,Stasiak M,Duechler M,Czyz ME

    更新日期:2012-06-01 00:00:00